J Immunol 161:6206–6214PubMed 24 Ang E, Liu Q, Qi M, Liu HG, Yan

J Immunol 161:6206–6214PubMed 24. Ang E, Liu Q, Qi M, Liu HG, Yang X, Chen H, Zheng MH, Xu J (2011) Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKL-induced activation of NF-κB and ERK. J Cell Biochem 112:89–97PubMedCrossRef 25. Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH (2010) Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal. Mol Pharmacol 77:17–25PubMedCrossRef

26. Walsh NC, Cahill M, Carninci P, Kawai J, Okazaki Y, Hayashizaki Y (2003) Multiple tissue-specific promoters control expression of the murine tartrate-resistant acid phosphatase gene. Gene 307:111–123PubMedCrossRef 27. Delaissé JM, Engsig MT, Everts V, del Carmen OM, Ferreras M, Lund L (2000) Proteinases in bone resorption: obvious and less obvious roles. Clin Chim Acta 291:223–234PubMedCrossRef 28. YAP-TEAD Inhibitor 1 in vitro Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T (1990) Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 87:7260–7264PubMedCrossRef

29. Islam S, Hassan F, Tumurkhuu G, Dagvadorj J, Koide N, Naiki Y, Yoshida T, Yokochi T (2008) Receptor activator of nuclear factor-kappa B ligand induces osteoclast formation in RAW 264.7 macrophage cells via augmented production of macrophage-colony-stimulating selleck chemicals factor. Micrbiol Immunol 52:585–590CrossRef 30. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A (1999) TRAF6 deficiency results in osteoporosis and defective interleukin-1, Src inhibitor CD40, and LPS signaling. Genes Dev 13:1015–1024PubMedCrossRef 31. Sakurai H, Chiba H, Miyoshi H, Sugita T, Yoriumi W (1999) IκB

(-)-p-Bromotetramisole Oxalate kinases phosphorylated NF-κB p65 subunit on serine 536 in the trasactivation domain. J Biol Chem 274:30353–30356PubMedCrossRef 32. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, Morita I, Wagner EF, Mak TW, Serfling E, Takayanagi H (2005) Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 202:1261–1269PubMedCrossRef 33. Kim K, Lee SH, Ha Kim J, Choi Y, Kim N (2008) NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol 22:176–185PubMedCrossRef 34. Song I, Kim JH, Kim K, Jin HM, Youn BU, Kim N (2009) Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation. FEBS Lett 583:2435–2440PubMedCrossRef 35. Yu M, Moreno JL, Stains JP, Keegan AD (2009) Complex regulation of tartrate-resistant acid phosphatase (TRAP) expression by interleukin 4 (IL-4): IL-4 indirectly suppresses receptor activator of NF-kappaB ligand (RANKL)-mediated TRAP expression but modestly induces its expression directly. J Biol Chem 284:32968–32979PubMedCrossRef 36.

Comments are closed.